Pharmaceutical company Eli Lilly is partnering with Collaborative Drug Discovery, a pharmaceutical and biotechnology data management company, to integrate their technologies.
Through the agreement, AI/ML drug discovery platform Lilly TuneLab will be integrated into CDD Vault software.
“By integrating TuneLab directly into CDD Vault, we are advancing CDD’s core vision to enable collaboration across drug discovery teams and organisations,” said CDD CEO and president Dr Barry Bunin.
Lilly TuneLab enables companies to access models trained on decades of Lilly’s research data. It provides access to AI/ML models for in silico property predictions across small molecules and antibody therapeutics. As companies contribute federated training data, the models become more accurate and generalisable.
In the agreement, biotechnology companies that use the CDD Vault electronic notebook will be able to use select Lilly predictive models within their natural scientific workflows.
“We believe that solving the most complex challenges in drug discovery will depend on innovative collaboration models that provide broad access to research data and empower chemists and biologists to make informed, data-driven decisions.
“TuneLab’s ADMET models will fit in our trusted secure CDD Vault software environment in natural workflows for experimental and computational scientists and with our growing CDD Vault ecosystem of biopharmaceutical companies.”
